Compare · JNJ vs LFVN
JNJ vs LFVN
Side-by-side comparison of Johnson & Johnson (JNJ) and Lifevantage Corporation (LFVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and LFVN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $653.54B, about 8373.9x LFVN ($78.0M).
- LFVN has been more active in the news (8 items in the past 4 weeks vs 6 for JNJ).
- JNJ has more recent analyst coverage (25 ratings vs 2 for LFVN).
- Company
- Johnson & Johnson
- Lifevantage Corporation
- Price
- -
- -
- Market cap
- $653.54B
- $78.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 6
- 8
- Recent ratings
- 25
- 2
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Lifevantage Corporation
LifeVantage Corporation engages in the identification, research, development, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, and skin and hair care products. The company offers Protandim, a line of scientifically-validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive system health; a line of weight management products under the PhysIQ brand; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes. It also provides anti-aging skin care products, including facial cleansers, perfecting lotions, eye serums, anti-aging creams, and hand creams, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. The company sells its products through its website, as well as through a network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, and China. LifeVantage Corporation is headquartered in Sandy, Utah.
Latest JNJ
- New insider Cavanaugh Thomas claimed ownership of 499 shares (SEC Form 3)
- Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
- FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
- EVP, WWC. Innovative Medicine Taubert Jennifer L exercised 15,000 shares at a strike of $115.67 and sold $3,950,400 worth of shares (15,000 units at $263.36) (SEC Form 4)
- CEO and Chairman of the Board Duato Joaquin exercised 123,291 shares at a strike of $115.67 and sold $32,199,927 worth of shares (123,291 units at $261.17) (SEC Form 4)
- Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
- CEO and Chairman of the Board Duato Joaquin sold $12,515,010 worth of shares (48,480 units at $258.15), decreasing direct ownership by 15% to 275,967 units (SEC Form 4)
- EVP, Chief Legal Officer Forminard Elizabeth exercised 9,344 shares at a strike of $131.94 and sold $4,090,960 worth of shares (15,918 units at $257.00), decreasing direct ownership by 28% to 16,994 units (SEC Form 4)
- SEC Form 13F-HR filed by Johnson & Johnson
- A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
Latest LFVN
- SEC Form 10-K filed by Lifevantage Corporation
- Lifevantage Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2026
- LifeVantage Declares Quarterly Dividend
- LifeVantage to Announce Fourth Quarter and Full Fiscal Year 2026 Results on August 27, 2026
- LifeVantage Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- President and CEO Moorehead Terrence was granted 308,642 shares (SEC Form 4)
- SEC Form 3 filed by new insider Moorehead Terrence
- LifeVantage Welcomes Terrence Moorehead as Chief Executive Officer
- Lifevantage Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits